Novel drug achieves high objective response rate in heavily pretreated chronic lymphocytic leukemia
Cancer Network News highlights UC-led research
Cancer Network News highlighted research led by the University of Cincinnati Cancer Center's Zulfa Omer that found a novel drug was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Omer, MD, Cancer Center member and assistant professor in the Department of Internal Medicine in UC's College of Medicine, and colleagues shared data from the Phase 1 NX-5948-301 trial at the 2025 European Hematology Association Congress.
The trial is testing a novel drug called bexobrutideg that targets the BTK enzyme in a population of heavily pretreated patients with advanced CLL. The drug was found to be well tolerated at all dose levels.
At a median follow-up of 9 months, 80.9% of patients had an objective response, meaning a complete or partial response to the treatment. Out of 48 patients enrolled, seven patients had stable disease, meaning the cancer did not progress or decrease while being treated with the drug. Two patients experienced disease progression.
“Robust and deepening responses were observed [with bexobrutideg]. Responses were rapid, with a median time to first response of 1.87 months,” Omer and her study coauthors wrote in the poster presentation. “...Of 18 patients treated for more than 12 months, 17 remain on the study, [and] 1 patient is approaching 2.5 years on treatment.”
Read the Cancer Network News article.
Featured photo at top of CLL cells viewed under a microscope. Photo/jxfzsy/iStock Photo.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.